English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/129280
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

NLRP3 inflammasome is activated in fibromyalgia: The effect of coenzyme Q10

AuthorsCordero, Mario D. ; Alcocer-Gómez, Elísabet; Carrión Rodríguez, Ángel Manuel ; Miguel, Manuel de; Díaz-Parrado, Eduardo; Bullón, Pedro; Battino, Maurizio; Sánchez-Alcázar, José Antonio
Issue Date2014
PublisherMary Ann Liebert
CitationAntioxidants and Redox Signaling 20(8): 1169-1180 (2014)
Abstract[Aims]: Fibromyalgia (FM) is a prevalent chronic pain syndrome characterized by generalized hyperalgesia associated with a wide spectrum of symptoms such as fatigue and joint stiffness. Diagnosis of FM is difficult due to the lack of reliable diagnostic biomarkers, while treatment is largely inadequate. We have investigated the role of coenzyme Q10 (CoQ10) deficiency and mitochondrial dysfunction in inflammasome activation in blood cells from FM patients, and in vitro and in vivo CoQ10 deficiency models. [Results]: Mitochondrial dysfunction was accompanied by increased protein expression of interleukin (IL)-1ß, NLRP3 (NOD-like receptor family, pyrin domain containing 3) and caspase-1 activation, and an increase of serum levels of proinflammatory cytokines (IL-1ß and IL-18). CoQ10 deficiency induced by p-aminobenzoate treatment in blood mononuclear cells and mice showed NLRP3 inflammasome activation with marked algesia. A placebo-controlled trial of CoQ10 in FM patients has shown a reduced NLRP3 inflammasome activation and IL-1ß and IL-18 serum levels. [Innovation]: These results show an important role for the NLRP3 inflammasome in the pathogenesis of FM, and the capacity of CoQ10 in the control of inflammasome. Conclusion: These findings provide new insights into the pathogenesis of FM and suggest that NLRP3 inflammasome inhibition represents a new therapeutic intervention for the disease.
URIhttp://hdl.handle.net/10261/129280
DOI10.1089/ars.2013.5198
Identifiersdoi: 10.1089/ars.2013.5198
issn: 1523-0864
e-issn: 1557-7716
Appears in Collections:(CABD) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.